GLP Preclinical Study Completed, Paving Way for FDA Submission
AMIX has more than doubled off its 52-week low of $2.44 on light trading volume (0.1× avg).
Summary
Autonomix completed its GLP preclinical study, a critical regulatory milestone that supports the upcoming FDA submission for its nerve-targeted platform. Final histology and lab analyses confirmed positive safety and performance outcomes in porcine models. This follows the company's recent reverse split and Nasdaq compliance regain, and adds to the positive clinical data reported earlier this year. The study data are expected to form a key part of the regulatory package, moving the technology closer to clinical-stage execution. With a market cap under $9M, this de-risking event is material for a pre-revenue medtech.
At the time of this announcement, AMIX was trading at $8.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.9M. The 52-week trading range was $2.44 to $32.55. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.